Source: Zacks Investment Research

Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).

Source: Zacks Investment Research

Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.

Source: GlobeNewswire Inc.

GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.

Source: GlobeNewswire Inc.

The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

Source: The Motley Fool

Labcorp Holdings stock fell 3.3% after the Centers for Medicare & Medicaid Services announced plans to reduce lab testing reimbursement rates by 15% starting next year, with potential additional cuts through 2029. Since CMS accounts for approximately 8% of Labcorp's revenue, a full 15% reduction would decrease annual revenue by 1.2%, with a worst-case scenario of 3.6% reduction if cuts continue through 2029. The stock's decline appears to have already priced in this worst-case scenario.

Source: GlobeNewswire Inc.

The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

Source: GlobeNewswire Inc.

The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

Source: GlobeNewswire Inc.

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

Source: GlobeNewswire Inc.

The global animal testing and non-animal alternative testing market reached $15.19 billion in 2025 and is projected to grow to $23.01 billion by 2035 at a CAGR of 4-4.5%. While animal testing dominated with 80.1% market share in 2025, non-animal alternative testing is expected to grow faster at 6.3% CAGR through 2030, driven by advances in organ-on-chip, organoids, AI biosimulation, and genomics. The pharmaceutical industry led end-user applications with 50.1% market share, while North America was the largest regional market at 38.6% of global revenue.

Source: GlobeNewswire Inc.

Testie Health, a consumer health company founded by Thea Rose, has launched nationwide with a direct-to-lab STI testing model that allows customers to purchase testing panels online and visit nearby laboratories for sample collection without scheduling a doctor's appointment. The service aims to destigmatize routine STI testing and make it a normal part of preventive healthcare, with results delivered within 48 hours and licensed provider support available for positive results.